GGrantIndex
Sort

82,697 grants matching vaccine development

Heat Shock Protein and Thermal Therapy of Cancer

$1,349,240
Roswell Park Cancer Institute Corp · P01 · FY2004 · CA

Task X19: Development of Assays and Reagents for Zika Virus Vaccines

$1,349,169
Randi Hornback · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2018 · AI

A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

$1,348,882
David M. Margolis · Univ Of North Carolina Chapel Hill · U01 · FY2016 · AI

A Pilot Trial of the effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

$1,348,882
David M. Margolis · Univ Of North Carolina Chapel Hill · U01 · FY2018 · AI

Flavivirus Infections: Pathogenesis and Prevention

$1,348,663
Univ Of Massachusetts Med Sch Worcester · P01 · FY2003 · AI

Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid Receptors

$1,348,462
Kenner Rice · National Institute On Drug Abuse · ZIA · FY2017 · DA

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH

$1,348,156
Daniel Ernest Ford · Johns Hopkins University · UL1 · FY2009 · RR

Vector-Borne Diseases: Biology Of Vector Host Relationship

$1,348,022
Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

EFFICACY OF DNA AND PROTEIN CO-IMMUNIZATION PROTOCOL TO PROTECT MACAQUES FORM SHIV INFECTION

$1,347,763
Marx Preston · Tulane University Of Louisiana · N01 · FY2016 · AI

Epitope-focused vaccine strategies against Zika virus

$1,347,756
Michel C Nussenzweig · Rockefeller University · P01 · FY2020 · AI

Epitope-focused vaccine strategies against Zika virus

$1,347,756
Michel C Nussenzweig · Rockefeller University · P01 · FY2019 · AI

Epitope-focused vaccine strategies against Zika virus

$1,347,756
Michel C Nussenzweig · Rockefeller University · P01 · FY2021 · AI

Epitope-focused vaccine strategies against Zika virus

$1,347,756
Michel C Nussenzweig · Rockefeller University · P01 · FY2022 · AI

Influenza Viral Pathogenesis

$1,347,530
Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

San Francisco Bay Clinical Trials Unit (CTU)

$1,347,336
Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2021 · AI

Immunity to Pneumonic Tularemia

$1,347,335
Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

Preclinical Studies of Bunyaviruses

$1,347,089
Brian Murphy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI

Core A: Husbandry & Management Core

$1,346,834
Cassandra Cullin · Oregon Health & Science University · U42 · FY2024 · OD

Host-Tumor Cell Interactions in Myeloma:

$1,346,410
Kenneth C Anderson · Dana-Farber Cancer Inst · P01 · FY2008 · CA

Molecular approaches to understand vector-host and vector-pathogen interactions

$1,346,111
Jesus Valenzuela · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

IND-enabling Preclinical Studies for Aβ and Dual Aβ/Tau MultiTEP platform-based AD Vaccines

$1,346,072
Michael G Agadjanyan · Institute For Molecular Medicine · U01 · FY2021 · AG

Pediatric AIDS Clinical Trials Unit

$1,345,731
Children'S Memorial Hospital (Chicago) · U01 · FY2002 · AI

Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies

$1,345,576
Alon Herschhorn · University Of Minnesota · U01 · FY2025 · AI

Control of Epidemic Influenza

$1,345,512
Baylor College Of Medicine · R01 · FY2004 · AI

Optimization of HIV glycoproteins as vaccine candidates

$1,345,369
Jose A Lasalde-Dominicci · University Of Puerto Rico · R01 · FY2017 · AI